Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Olaparib plus bevacizumab bij ovariumcarcinoom: definitieve OS-resultaten van PAOLA-1
aug 2023 | Gynaecologische oncologie